STUDY OF HUMAN-IMMUNODEFICIENCY-VIRUS RESISTANCE TO 2'-3'-DIDEOXYINOSINE AND ZIDOVUDINE IN SEQUENTIAL ISOLATES FROM PEDIATRIC-PATIENTS ON LONG-TERM THERAPY

被引:19
作者
DIMITROV, DH
HOLLINGER, FB
BAKER, CJ
KLINE, MW
DOYLE, M
BREMER, JW
SHEARER, WT
机构
[1] BAYLOR COLL MED,DIV MOLEC VIROL,1 BAYLOR PLAZA,HOUSTON,TX 77030
[2] BAYLOR COLL MED,DEPT PEDIAT,INFECT DIS SECT,HOUSTON,TX 77030
[3] BAYLOR COLL MED,ALLERGY & IMMUNOL SECT,HOUSTON,TX 77030
[4] TEXAS CHILDRENS HOSP,HOUSTON,TX 77030
[5] VET ADM MED CTR,REG CTR AIDS & HIV INFECT,HOUSTON,TX 77211
[6] UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225
关键词
D O I
10.1093/infdis/167.4.818
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Resistance to zidovudine (3'-azido-3-deoxythymidine) and 2',3'-dideoxyinosine (ddl) has been reported for human immunodeficiency virus (HIV) isolates from adults, but little is known about these drugs in children. A new micrococulture assay was developed for evaluation of drug susceptibility using single-passage HIV isolates cocultured with peripheral blood mononuclear cells from healthy donors. HIV isolates from children treated with zidovudine or ddl were evaluated to define the emergence of resistance to these antiretroviral agents. Four patients were treated with ddl and 3 with zidovudine for > 1 5 months. There was a greater-than-or-equal-to 20-fold decrease in susceptibility to ddl for sequential isolates of HIV recovered from 4 patients treated with ddl for 22-31 months and a 4- to 10-fold decrease in susceptibility to zidovudine in 3 patients. HIV isolates from 3 patients treated with ddl or zidovudine alone showed a minor amount of cross-resistance to the other antiretroviral agent. Results indicate the importance of monitoring antiretroviral drug susceptibility of HIV isolates when assessing clinical deterioration in children treated for > 1 year.
引用
收藏
页码:818 / 823
页数:6
相关论文
共 41 条
[31]  
RICHMAN DD, 1990, AM J MED, V88, P5
[32]   BIOLOGICAL COMPARISON OF WILD-TYPE AND ZIDOVUDINE-RESISTANT ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM THE SAME SUBJECTS - SUSCEPTIBILITY AND RESISTANCE TO OTHER DRUGS [J].
ROOKE, R ;
PARNIAK, MA ;
TREMBLAY, M ;
SOUDEYNS, H ;
LI, XG ;
GAO, Q ;
YAO, XJ ;
WAINBERG, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (05) :988-991
[33]  
RUBSAMENWAIGMAN.H, 1991, INFECTION, V19, P77
[34]  
SKOWRON G, 1990, AM J MED S5B, V88, P20
[35]   RESISTANCE TO DDI AND SENSITIVITY TO AZT INDUCED BY A MUTATION IN HIV-1 REVERSE-TRANSCRIPTASE [J].
STCLAIR, MH ;
MARTIN, JL ;
TUDORWILLIAMS, G ;
BACH, MC ;
VAVRO, CL ;
KING, DM ;
KELLAM, P ;
KEMP, SD ;
LARDER, BA .
SCIENCE, 1991, 253 (5027) :1557-1559
[36]   EVIDENCE FOR A ROLE OF VIRULENT HUMAN IMMUNODEFICIENCY VIRUS (HIV) VARIANTS IN THE PATHOGENESIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME - STUDIES ON SEQUENTIAL HIV ISOLATES [J].
TERSMETTE, M ;
GRUTERS, RA ;
DEWOLF, F ;
DEGOEDE, REY ;
LANGE, JMA ;
SCHELLEKENS, PTA ;
GOUDSMIT, J ;
HUISMAN, HG ;
MIEDEMA, F .
JOURNAL OF VIROLOGY, 1989, 63 (05) :2118-2125
[37]   LONG-TERM TOXICITY ACTIVITY PROFILE OF 2',3'-DIDEOXYINOSINE IN AIDS OR AIDS-RELATED COMPLEX [J].
YARCHOAN, R ;
PLUDA, JM ;
THOMAS, RV ;
MITSUYA, H ;
BROUWERS, P ;
WYVILL, KM ;
HARTMAN, N ;
JOHNS, DG ;
BRODER, S .
LANCET, 1990, 336 (8714) :526-529
[38]  
YARCHOAN R, 1988, LANCET, V1, P76
[39]  
Zurlo J J, 1990, Md Med J, V39, P161
[40]  
1990, AM J MED, V89, P335